权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mitochondrial dysfunction and tau pathology in Alzheimer's disease

阿尔茨海默病中的线粒体功能障碍和 tau 病理学

基本信息

批准号：
10805120
负责人：
Gail V. W. Johnson
金额：
$ 42.35万
依托单位：
UNIVERSITY OF ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-16 至 2025-09-15
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10805120
关键词：
3-Dimensional 3xTg-AD mouse Address Adult Affect Age Aging Alzheimer&apos s Disease Alzheimer&apos s disease brain Alzheimer&apos s disease pathology Alzheimer&apos s disease patient Animals Attenuated Bilateral Bioenergetics Biological Models Biology Brain Cells Complex Data Data Set Dementia Development Disease Disease Progression Electron Transport Etiology Event Evolution Exhibits Future Genes Harvest Hippocampus Hypoxia Impairment Injections Intervention Investigation Light Link Measures Metabolic Metabolism Mitochondria Modeling Modification Morphology Mus Neuronal Dysfunction Neurons Nucleic Acids Oxidative Phosphorylation Oxidative Stress Pathogenesis Pathologic Pathology Photosensitizing Agents Production Proteins Proton Pump Proton-Motive Force Protons Reactive Oxygen Species Research Role Slice Study models Symptoms System Tauopathies Technology Testing Therapeutic Time Toxin abeta oligomer experimental study in vivo in vivo Model innovation insight macromolecule mitochondrial dysfunction mouse model neonatal brain new technology novel optogenetics oxidation oxidized lipid preservation prevent response spatiotemporal stress granule tau Proteins tau aggregation tau-1 therapeutic development tool wireless wireless implant

项目摘要

Alzheimer’s disease (AD) is the most common cause of dementia with no current interventions that halt or substantially slow disease progression. AD is a multifactorial disease characterized by impaired mitochondrial bioenergetics, oxidative stress, and tau pathology. These AD pathologies are interconnected, change over time, and correlate with neuronal dysfunction. Moreover, the hallmarks are dynamic and difficult to isolate experimentally, which makes assigning causation challenging and limits therapeutic development. This proposal uses novel optogenetic technology developed for hypoxic biology to address this gap and test if mitochondrial dysfunction and reactive oxygen species (ROS) production are causal for the progression of tau pathology. Our approach involves directly controlling mitochondrial function and ROS production using light, without interfering with metabolism or using irreversible toxins with off-target effects. The optogenetic tools mitochondria-ON (mtON) and mitochondria-OFF (mtOFF) are mitochondria-targeted light-activated proton pumps that alter mitochondrial bioenergetics to turn ‘on’ or ‘off’ mitochondrial function in response to light. Similarly, mtSuperNova is a mitochondria-targeted genetically-encoded photosensitizer which generates ROS in response to light. These tools will spatiotemporally control mitochondrial function and ROS production in both an ex vivo brain slice culture and an in vivo mouse model using the PS19 mouse line (P301S tau). These mice exhibit early mitochondrial dysfunction and have been used extensively to study tau pathology and are an optimal model for these studies. Organotypic brain slice cultures will be used to provide a three-dimensional system to mechanistically test when and how mitochondrial energetics and ROS production contribute to pathological tau modifications. AD is largely associated with aging; therefore, in we will bridge our ex vivo findings into an adult in vivo model. Using a wireless optogenetic system, we will illuminate hippocampi in live, freely moving PS19 adult mice to test the effect of mitochondrial dysfunction over time on measures of oxidative stress and tau pathology. Mitochondrial dysfunction and ROS production have long been associated with AD pathology however the cause-and-effect relationship is unclear. Our novel technology provides an approach to directly test the role of mitochondria in AD independent of confounding factors. Overall, these studies will begin to clearly define the role of mitochondria in the evolution of tau pathology and provide mechanistic insights into therapeutic opportunities to attenuate AD pathogenesis.

阿尔茨海默病（AD）是痴呆症的最常见原因，目前没有干预措施可以阻止或阻止